Servier China

Servier is an international pharmaceutical group, governed by a non-profit foundation, with headquarter in Suresnes, France. Servier was one of the first multinational pharmaceutical companies came to China 45 years ago. Over the decades, Servier China has grown into a dynamic company standing as a firm and consistent leader in the management of cardiovascular diseases and diabetes, venous disease, providing medical solutions to 3 million Chinese patients every day. Servier actively expanded its landscape to the field of hard-to-treat oncology, e.g colorectal cancer, glioma and liquid tumor. Servier China is operating with three key business sectors including commercial operation, R&D and production, with employees. Up to now, the business operation covers 27 provinces and cities in China. Servier China established its R&D capacity in 2001 and is focused on the development of innovative medicines for China and dedicated its research therapeutic areas in immune-inflammatory diseases, neuropsychiatry and oncology. The production plant of Servier is located in Tianjin and committed to ensuring the availability of Servier’s leading brands to patients in China and some Asian countries. In 2020, Tianjin Plant built operating base to further support clinical research of pancreatic and rectal cancer in China. Its production capability is expanded to 120 million standard boxes to meet more patient needs. For medical information or to report a side effect, please vist servier.com.cn.